Supplemental online content for:

**A Multidisciplinary Toxicity Team for Cancer Immunotherapy–Related Adverse Events**

Jarushka Naidoo, MBBCh; Jiajia Zhang, MD, PhD; Evan J. Lipson, MD; Patrick M. Forde, MBBCh; Karthik Suresh, MD; Kendall F. Moseley, MD; Seema Mehta, MD; Shawn G. Kwatra, MD; Alyssa M. Parian, MD; Amy K. Kim, MD; John C. Probasco, MD, PhD; Rosanne Rouf, MD; Jennifer E. Thorne, MD, PhD; Satish Shanbhag, MD; Joanne Riemer, RN, BSN; Ami A. Shah, MD; Drew M. Pardoll, MD, PhD; Clifton O. Bingham III, MD; Julie R. Brahmer, MD, MHS; and Laura C. Cappelli, MD, MHS


**eFigure 1:** Representative Templates to and From IR-Tox Team  
**eFigure 2:** CONSORT Diagram  
**eFigure 3:** Selected Results of the Electronic Postpilot Survey  
**eAppendix 1:** Postpilot Questionnaire About the IR-Tox Team  
**eAppendix 2:** Clinical Outcomes of Confirmed irAEs
**eFigure 1.** Representative templates of information included for (A) referral to IR-tox team and (B) recommendations provided by IR-tox team 24 hours after referral. Abbreviation: IR-tox, immune-related toxicity.

**eFigure 2.** CONSORT diagram of patients referred to the IR-tox team. Abbreviations: IR-tox, immune-related toxicity; irAE, immune-related adverse event.
Did you find the IR-tox team service to be helpful?

- Definitely yes
- Probably yes
- Unsure
- Probably not
- Definitely not

What topic(s) did you ask the IR-tox team about?

- Whether to rechallenge with immunotherapy (after toxicity)
- Need for medicine referral for immune-related toxicity
- Whether to initiate immunotherapy in a particular patient
- Whether to continue immunotherapy
- Therapy for immune-related toxicity
- Diagnosis of immune-related toxicity

Future Uses for the IR-Tox Team

- Would you support an immune-related toxicity registry/enrollment of patients?
  - Yes
  - Maybe
  - No

- What other resources could the IR-tox team provide?
  - Educational materials about irAEs: patients
  - Educational materials about irAEs: providers
  - Immunosuppression prescribing materials
  - Electronic medical record order sets
  - Treatment algorithms irAEs
  - Algorithms for evaluation of irAEs

eFigure 3. Selected results of the electronic postpilot survey sent to oncology providers in the cancer center, after the IR-tox team pilot program. Abbreviations: IR-tox, immune-related toxicity; irAE, immune-related adverse event.
### eAppendix 1. Postpilot Questionnaire About the IR-Tox Team

Q1 What area of oncology do you primarily work in?
Q2 What type of provider are you?
Q3 How often do you prescribe immunotherapy for cancer treatment/evaluate patients on immunotherapy?
Q4 What kind of immunotherapy do you prescribe? (check all that apply)
Q5 How often do you encounter suspected immune-related toxicity?
Q6 How often do you encounter immune-related toxicity that requires an intervention?
Q7 Have you contacted the IR-tox team?
Q8 What topic(s) did you ask the team about? (check all that apply)
Q9 Did you use the specific suggestions provided by the IR-tox team?
Q10 Did the IR-tox team recommendations change your approach to evaluation or management of immune-related toxicity?
Q11 Did you find the IR-tox team service to be helpful?
Q12 What format would you prefer to contact the IR-tox team? (choose one)
Q13 What other resources could the IR-tox team provide that would be helpful? (check all that apply)
Q14 How would you prefer to access information on IR-tox?
Q15 Do you think there would be a benefit to a regular tumor board-style meeting about IR-tox?
Q16 How often should a tumor board-style meeting for IR-tox take place?
Q17 Would you support an immune-related toxicity registry/enrollment of patients with irAEs for research purposes?
Q18 Do you want a separate irAEs outpatient clinic?
Q19 Do you want a separate irAEs urgent care?
Q20 Would you attend an irAEs masterclass if offered?
Q21 Please provide any additional feedback

Abbreviations: IR-tox, immune-related toxicity; irAE, immune-related adverse event.

### eAppendix 2. Clinical Outcomes of Confirmed irAEs

<table>
<thead>
<tr>
<th>Clinical Outcomes</th>
<th>Grade 1–2 (n=47; 60%) n (%)</th>
<th>Grade ≥3 (n=32; 40%) n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>irAE1†</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Completely resolved</td>
<td>2 (4)</td>
<td>3 (9)</td>
</tr>
<tr>
<td>Improved</td>
<td>32 (68)</td>
<td>20 (63)</td>
</tr>
<tr>
<td>Stabilized</td>
<td>6 (13)</td>
<td>3 (9)</td>
</tr>
<tr>
<td>Worsened</td>
<td>0 (0)</td>
<td>3 (9)</td>
</tr>
<tr>
<td>irAE2‡</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Completely resolved</td>
<td>3 (7)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Improved</td>
<td>2 (4)</td>
<td>1 (3)</td>
</tr>
<tr>
<td>Stabilized</td>
<td>2 (4)</td>
<td>1 (3)</td>
</tr>
<tr>
<td>Worsened</td>
<td>0 (0)</td>
<td>1 (3)</td>
</tr>
</tbody>
</table>

Abbreviation: irAE, immune-related adverse event.
†First irAE prompting referral.
‡Second irAE prompting referral.